Author:
Stankov Metodi V.,Hoffmann Markus,Jauregui Rodrigo Gutierrez,Cossmann Anne,Ramos Gema Morillas,Graalmann Theresa,Friedrichsen Michaela,Ravens Inga,Ilievska Tamara,Ristenpart Jasmin,Schimrock Anja,Willenzon Stefanie,Ahrenstorf Gerrit,Witte Torsten,Förster Reinhold,Kempf Amy,Pöhlmann Stefan,Hammerschmidt Swantje I.,Alexandra Dopfer-Jablonka,Behrens Georg M. N.
Abstract
AbstractSARS-CoV-2 Omicron XBB subvariants efficiently evade immunity from prior infection or vaccination, requiring vaccine adaptation. Here, we analyzed immunogenicity of an adapted vaccine, BNT162b2 Omicron XBB.1.5, which is currently used for booster vaccination. Booster vaccination significantly increased anti-Spike IgG, accompanied by expansion of cross-reactive memory B cells recognizing Wuhan and Omicron XBB.1.5 spike variants. Geometric mean neutralizing titers against XBB.1.5, XBB.1.16 and XBB.2.3, as well as cross-reactive responses against EG.5.1 and BA.2.86 increased significantly relative to pre-booster titers. Finally, the number of Wuhan and XBB.1.5 spike reactive IFN-γ-producing T cells significantly increased after booster vaccination. In summary, BNT162b2 Omicron XBB.1.5 vaccination resulted in potent neutralizing antibody responses against Omicron XBB variants, including the recent Omicron variants EG.5.1 (Eris) and BA.2.86 (Pirola), as well as XBB.1.5 reactive T cell responses, suggesting that booster vaccination will augment protection against these emerging variants.
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. Chalkias, S. , et al. Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines. medRxiv, 2023.2008.2022.23293434 (2023).
2. Addetia, A. , et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature (2023).
3. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution;Nature,2023
4. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination;Nat Med,2021
5. Behrens, G.M.N. , et al. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Commun 13, 4872 (2022).